By Daniella Parra
Agilent Technologies (NYSE: A) said it’s acquiring BIOVECTRA, a Canadian CDMO, for $925 million.
The company said it will enhance Agilent’s biopharma solutions by expanding service offerings, adding expertise in fast-growing segments like ADCs and HPAPIs, and strengthening gene-editing capabilities. The deal, funded by cash and debt, is expected to close before 2025, pending regulatory approvals, it said.
“BIOVECTRA is excited to join Agilent, a company whose dedication to people and customers is very much aligned with ours,” said Oliver Technow, CEO of BIOVECTRA. “BIOVECTRA has dedicated nearly 55 years to the relentless pursuit of helping our customers solve complex problems that improve patients’ lives. This synergistic pairing of our capabilities with Agilent’s will further enhance the value we can offer to our customers.”
Contact:
Editor@executives-edge.com
